Midday Report: Taysha Gene Therapies (TSHA) Gains on June 23

Equities Staff  |

Today Taysha Gene Therapies Inc (NASDAQ: TSHA) is trading 9.04% higher.

The latest price, as of 12:13:30 est, was $3.71. Taysha Gene Therapies has climbed $0.31 so far today.

161,468 shares exchanged hands.

As of the previous close, Taysha Gene Therapies has a YTD change of 70.56%. The company anticipates its next earnings on 2022-08-15.

For technical charts, analysis, and more on Taysha Gene Therapies visit the company profile.

About Taysha Gene Therapies Inc

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.

To get more information on Taysha Gene Therapies Inc and to follow the company's latest updates, you can visit the company's profile page here: Taysha Gene Therapies Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content